14.4 C
New York
Wednesday, June 23, 2021

Caladrius Biosciences Inc (CLBS) Stock Rises 23% Today, But Why?

Caladrius Biosciences Inc (CLBS) stock price is increasing significantly in the pre-market session on Wednesday 10th March 2021. The stock price has been increased by 23.50% as of this writing.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



The reason behind the positive trend

The stock analysts at Brookline Capital Management increased their estimated price from $7.00 to $10.00.  Brookline Capital Management’s price target suggests a potential upside of 446.45% from the company’s current price. Caladrius Biosciences currently has a consensus rating of “Buy” and a consensus target price of $8.06.

Orphan Drug status for CLBS12 from FDA

On March 8, 2021, the Caladrius Biosciences announced that their CD34+ cell therapy, CLBS12, the product has received orphan drug designation from the U.S. Food and Drug Administration (“FDA”). The above-mentioned drug is used to treat Buerger’s disease, a condition which is related to critical limb ischemia (CLI) and it has no approved treatments to date in the U.S.

President and Chief Executive Officer of Caladrius. David J. Mazzo, PhD expresses his pleasure in the approval of CLBS12 as an orphan drug designation. He further said that their drug has shown strong results in Japan for the treatment of Buerger’s Disease. The company is now looking to discuss the next step with the FDA, which is the registration of CLBS12 in the USA.

The company announced its Q4 and full-year 2020 financial results on February 25, 2021.

Fourth Quarter and Full Year 2020 Financial Highlights

The company spent 2.9 million in the fourth quarter on Research and development expenses and $9.3 million for the year ended December 31, 2020. The company reported a net loss of $8.1 million for the year ended December 31, 2020, compared to $19.4 million for the year 2019. The company spent $2.5 million in General and administrative expenses in the fourth quarter and $9.9 million for the year ended December 31, 2020. The company reported earnings of $0.28 per share for the quarter, missing the analyst’s estimates of ($0.27) by ($0.01).

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.